WOS
Permanent URI for this collectionhttps://hdl.handle.net/11443/932
Browse
Search Results
Item Lorlatinib in ALK- or ROS1-Positive Non-Small Cell Lung Cancer Patients: Experience from an Early Access Program in Turkey(2019-01-01) Kilickap, S.; Demirci, U.; Bugdayci, F.; Tural, D.; Korkmaz, T.; Paydas, S.; Yilmaz, C.; Turna, H.; Sezer, A.; Cinkir, H. Yesil; Okutur, K.; Erman, M.; Eralp, Y.; Cabuk, D.; Isikdogan, A.; Demirkazik, A.; Karaoglu, A.; Yazilitas, D.; Senler, F. Cay; Yumuk, P. F.; Coskun, H.; Yildiz, I.; Oztop, I.; Beypinar, I.; Aydin, K.; Kaplan, M.; Meydan, N.; Olmez, O. F.; Ozyilkan, O.; Seber, S.; Arslan, C.; Sendur, M. A.; Cicin, I.Item Are Pretreatment Inflammation-Based Prognostic Scores Useful in Predicting the Outcomes of Patients with ALK-Positive NSCLC?(2019-01-01) Olmez, O. F.; Bilici, A.; Gursoy, P.; Cubukcu, E.; Yildiz, O.; Sakin, A.; Korkmaz, T.; Cil, I.; Cakar, B.; Menekse, S.; Demir, T.; Acikgoz, O.; Hamdard, J.Item Systemic Inflammatory Markers as a Predictors of Response to Crizotinib in Patients with ALK-Positive Non-Small-Cell Lung Cancer(2019-01-01) Bilici, A.; Olmez, O. F.; Gursoy, P.; Cubukcu, E.; Yildiz, O.; Sakin, A.; Korkmaz, T.; Cil, I.; Cakar, B.; Menekse, S.; Demir, T.; Acikgoz, O.; Hamdard, J.